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The screeningandcareful selectionof excipients is a critical step inpaediatric formulationdevelopment as
certain excipients acceptable in adult formulations,maynotbe appropriate for paediatric use.While there
is extensive toxicity data that could help in better understanding and highlighting the gaps in toxicity
studies, the data are often scattered around the information sources and saddled with incompatible data
types and formats.
This paper is the second in a series that presents the update on the Safety and Toxicity of Excipients for
Paediatrics (“STEP”) database being developed by Eu-US PFIs, and describes the architecture data ﬁelds
and functions of the database. The STEP database is a user designed resource that compiles the safety
and toxicity data of excipients that is scattered over various sources and presents it in one freely acces-
sible source. Currently, in the pilot database data from over 2000 references/10 excipients presenting
preclinical, clinical, regulatory information and toxicological reviews, with references and source links.
The STEP database allows searching “FOR” excipients and “BY” excipients. This dual nature of the STEP
database, in which toxicity and safety information can be searched in both directions, makes it unique
from existing sources. If the pilot is successful, the aim is to increase the number of excipients in the
existing database so that a database large enough to be of practical research use will be available. It is
anticipated that this source will prove to be a useful platform for data management and data exchange
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1. Background
The development of an appropriate paediatric formulation is
a complex task that requires multiple considerations. Amidst the
several challenges, such as acceptable palatability, age appro-
priateness, dosage forms and dosing devices, is the selection of
“suitably safe excipients” (Maldonado and Schaufelberger, 2011).
The screening and careful selection of excipients is a critical step in
paediatric formulation development as certain excipients accept-
able in adult formulations, may not be appropriate for paediatric
use, e.g. ethanol in oral liquids or benzyl alcohol in intravenous
formulations for neonates. During infancy and childhood, there is
rapid growth and development with age-related changes in the
various organs, body composition, protein binding, active trans-
port mechanisms and metabolic pathways. Therefore, paediatric
patients and in particular neonates and infants, may not be able to
metabolize or eliminate an ingredient in the same manner as adult
and so in some instances this may lead to deleterious side effects
(CHMP, 2006).
The toxicity of excipients may differ between adult and pae-
diatric patients and across the paediatric sub-sets e.g. preterm
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to a fully released database and will eventually include many
excipients.
2 The European Paediatric Formulation Initiative (EuPFI) is a consortium founded
in 2007 and working in a pre-competitive way on paediatric drug formulations.
Members are from academia, hospital pharmacies, pharmaceutical industry (Inno-
vators, Generics, Contract Research Organizations (CRO), Specials and Excipient
Manufacturers) with European Medicine Agency (EMA) as an observer. The main
objective of the members is to resolve scientiﬁc, regulatory and technological issues
associated with paediatric formulation development.S. Salunke et al. / International Journ
eonates may be at increased risk of propylene glycol-associated
dverse events due to diminished ability to metabolize propyl-
ne glycol, thereby leading to accumulation and potential adverse
vents (FDA, 2011). Depending on the active substance and excip-
ents, appropriate use of the medicinal product in the newborn
ay require a new formulation or appropriate information about
ilution of an existing formulation. Although basic considerations
egarding the use of a speciﬁc excipient in a medicinal product
re not different for adult and paediatric medicines, the inclu-
ion of any excipient in a paediatric medicine requires additional
isk assessment focusing on potential safety concerns. Risks to
hildren andparticularly to neonates have been emphasized in sev-
ral publications (Ernest et al., 2007; Fabiano et al., 2011; Ursino
t al., 2011) and also recognized by the regulatory agencies (Carter,
011).
There are many literature reports about the possible adverse
ffects of pharmaceutical excipients in the paediatric population,
nd if children are taking multiple medications they may be
xposed to several potentially toxic doses of excipients while
eceiving routine treatment. For instance, benzyl alcohol, pro-
ylene glycol and polysorbate 80 co-administration resulted in
arious toxicological syndromes in paediatric populations espe-
ially neonates (Shehab et al., 2009; Kulo et al., 2012; Balistreri
t al., 1986). In particular, hospitalized neonates have received
edicines with potentially harmful drug formulation excipients
Lass et al., 2012). It is possible that even if the excipient is known
o be potentially harmful, the daily intake will not exceed the toxic
hreshold due to the small quantities used in drug formulations.
owever, the general lack of quantitative information of the
xcipient amount in the Summary of Product Characteristics
SmPC) makes it difﬁcult for the practitioner to readily making
n informed decision. The extent of possible harm caused by the
ormulation excipients has not been established. Potentially harm-
ul excipients need careful safety assessment and determination
f the pharmacokinetic/pharmacodynamic (PK/PD) proﬁles in
aediatrics (Allegaert et al., 2010).
An increased public awareness about the hazards and toxicity of
hese excipients has encouraged the development of technologies
or their remediation. The way forward is to understand better and
redict potential toxicities at an early stage of drug development,
o gain deeper insights into the biology and underlying toxicity,
ndmakedecisionswell before committing to furtherdevelopment
nd clinical trials. The combination of traditional toxicology meth-
ds with new strategies and tools for integrating high-throughput
ranscriptomics, proteomics, and metabolomics data could help to
ork towards the goal (Guengerich and MacDonald, 2007). How-
ver, the greatest challenge associatedwith productive evaluations
s the availability of existing data. As excipients were generally
onsidered inert and assumed to be safe in children on the basis
f adult data, there are very limited studies about the extent to
hich children, especially premature babies and neonates, are
xposed to excipients and the safety related to their use (Nunn
nd Williams, 2005). Also many traditional and commonly used
xcipients have not undergone rigorous toxicological assessment.
here is still a gap between the research performed and the avail-
ble evidence base in paediatrics compared to that in adults. There
s an urgent need to identify and ﬁll in the gaps in toxicologi-
al assessment of excipients. Information about the possible harm
esulting from excipients and also the quantitative data regarding
he excipient amounts in speciﬁc drug products should be made
vailable to pharmacists, drug development scientists and paedia-
ricians. This will assist the selection of appropriate medicines for
he paediatric population and support the development of paedi-
tric medicines. When excipients cannot be avoided, professionals
hould have access to quantitative and qualitative information that
llows them to assess risk. The existing public sources do notharmaceutics 457 (2013) 310–322 311
provide complete and/or comparative information on safe use and
acceptability of excipients in paediatrics. While there is exten-
sive toxicity data that could help in better understanding and
highlighting the gaps in toxicity studies, the data are often scat-
tered around and saddled with incompatible data types, formats,
databases, and analysis tools. Finally much information such as
description of experimental methods, details about test, dosage
regimen, etc., is often stored as free text format which is not easy
to search. To be able to derive informed decisions in an efﬁcient
way, in a short time, it was necessary to integrate the safety and
toxicity information of excipients from disparate resources under
one umbrella and design and establish a tool for easy, quick and
reliable access of this information. Thus, the development of aweb-
based database of Safety and Toxicity of Excipients for Paediatrics
(“STEP”) has been undertaken collaboratively by European (Eu)2
and United States (US)3 Paediatric Formulation Initiatives (PFIs).
The aim is to gather and extract in systematic way the available
toxicity and safety information and organize it into a searchable
system allowing datamining, visualization and analysis to discover
useful information from collected data sets. This freely/publicly
accessible source will help enhance the evidence base of safety and
toxicity information of excipients for the pharmaceutical indus-
try, academics, pharmacists, clinicians and regulators to make
informed decisions and thus expedite paediatric drug develop-
ment.
The establishment of successful data sharing strategies requires
buy-in from end-users and agreement on the content, struc-
ture and format of the database. Furthermore, it is advisable to
obtain a solid understanding of the original purpose of the data,
because the way those data were collected and veriﬁed or vali-
dated will help shape or limit their use in the database. Hence,
the pilot database development was planned after determining
the needs captured through the global need assessment survey
(Salunke et al., 2012). The need assessment study focussed on
the factors inﬂuencing the decision that the database should be
implemented and this pilot study focuses on how it should be
implemented. The intention is to identify potential concerns and
challenges, such as data collection strategy, data curation meth-
ods, handling data difﬁcult to access or curate, and practical issues
in data quality assessments. This information can then be used
to modify the database components and reach improved ﬁnal
product.
Through the present pilot database the aim is to assess com-
prehension, acceptance, feasibility, and other factors that inﬂuence
how readily the database will meet the needs captured from the
end-users and how well it will facilitate their workﬂow
After the development phase, the pilot version of the STEP
database compiling the data for 10 prioritized excipients is
now available for beta testing from the EuPFI website. If the
pilot is proved to be successful, the database will be expanded3 The United States Paediatric Formulation Initiative (US-PFI) is a project of the
Eunice Kennedy Shriver National Institute of Child Health andHumanDevelopment
(NICHD). The PFIwas established in 2005 to address the issue of the lack of appropri-
ate formulations in children and to use this activity as ameans to improve paediatric
formulations.
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. Technical details
.1. Functional requirements
The STEP Database is a “user-designed” resource for “users” and
ompiles the safety and toxicity data of excipients that is scattered
ver various sources and presents it in one freely accessible source.
he critical appraisal of the references is out of scope of the STEP
atabase and so thedatabasewill not provide any interpretive com-
ents. Hence, a userwill be encouraged to access such information
t the source/link provided. Also, the responsibility of interpreting
nd using this information appropriately will always remain with
he end-users.
The following content and structure requirements were formu-
ated from the global need assessment survey aforementioned:
. Content:
• Experimental details and results from in vivo animal experi-
ments, in vitro experiments, human safety and toxicity studies
and epidemiology data.
• Regulatory information and toxicological reviews.
. Structure:
• Provide the information in tabular/granular format.
• Enable viewing and ﬁltering/reﬁning the information to facil-
itate the Users’ needs.
• Create a search tool to accommodate complex queries.
• Allowexportingoutcomedata intoPDF,WordandExcel formatas needed.
• The design should be sufﬁciently ﬂexible to allow necessary
modiﬁcations andyetmaintain backward compatibility for the
components existing in the system.registration page.
2.2. General structure of the database
The database is organized in six sections functioning in parallel
(1) General Information, (2) Clinical Data, (3) Non-Clinical Data, (4)
In Vitro Data, (5) Regulatory References and (6) Reviews. Each sec-
tion is detailed in paragraphs below. The STEP database will be free
and publicly accessible through EuPFI website but it will require
registration and authorization of the password.
3. Database construction and content
3.1. Database architecture
The database is built up on an intuitive search interface and
results display. The launching page expedites sign-up process with
established credentials, and provides account registration form for
the ﬁrst time users (Fig. 1). On successful registration the user is
issued a password and subsequently can access the database with
their email ID and password.
3.1.1. Search interface
The search interface offers two search modules: “Search by
Excipient” and “Search for Excipients”. “Search by Excipient” mod-
ule provides navigation tools for selection of speciﬁc excipients and
should be used when searching for safety and toxicity information
of particular excipients. It allows for browsing by alphabeti-
cally sorted excipients’ names, selecting an excipient or multiple
excipients, or by browsing and selecting additional excipents’ iden-
tiﬁcation options:1. Chemical name/Synonyms
2. CAS number (the unique, universal, numeric chemical substance
identiﬁers)
3. Functionality of excipients
S. Salunke et al. / International Journal of Pharmaceutics 457 (2013) 310–322 313
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Fig. 2 is the screen shot of “Search by Excipients” module
llustrating how the user can search by the excipients name (e.g.
ropylene glycol), or synonym (e.g. 1,2 propanediol), or CAS num-
er (e.g. 57-55-6) or functionality of the excipient (e.g. Solvents,
reservatives).
The searches can be performed by either selecting the options
vailable in the drop down menu or by typing only partial name
n the “Excipient Name” search box with autocomplete/suggestion
apability and selecting name from suggested list. For instance, if
he user types “ben” in the excipient name box, the systemwill give
enzoic acid, benzyl alcohol, benzyl paraben, etc. in the drop down
ox as indicated in Fig. 3. Fig. 4 shows how search can be performed
y selecting the excipients in the dropdownbox. On submitting the
uery, the user is directed to the search results page.
The “Search for Excipients” module provides enhanced tools for
omplex queries allowing for searching for excipients associated
ith speciﬁc studies, effects or pharmacological functions (Fig. 5).
Fig. 3. Screen shot of searching the excipients by typinby Excipients module.
The users can ﬁnd the excipients by their adverse effect, adminis-
tration age, study type and/or route of administration (e.g. which
excipients are administered in infants by intravenous route).
3.1.2. Search results display
The “Search Results” from a database query are presented in
tabular format (Fig. 6) and can be sorted, reﬁned and exported
according to the user needs.
Each element of the Search Result display is discussed in more
details in following section
3.1.2.1. General information. This section is structured to provide
the basic/descriptive information of the excipient in an easily
readable format. Table format is provided to summarize the infor-
mation and to help the users to screen the information at a glance
(Fig. 7). The section lists identiﬁcation information including Excip-
ient’s name, key Synonyms and CAS number. The identiﬁcation
g three letters of the excipients to be searched.
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nformation particularly excipient chemical name, synonyms and
AS number are as according to the Handbook of Pharmaceutical
xcipients (Roweet al., 2012) for pilot database. Additional identiﬁ-
ation data and chemical and physical properties of excipients such
s chemical common name, chemical formula or molecular weight
ight be retrieved via link to the ChemID database (Tomasulo,
002). ChemID is a free, web-based search system that provides
ccess to structure and nomenclature authority ﬁles used for the
dentiﬁcation of chemical substances cited in National Library of
edicine (NLM) databases, including the TOXNET® system.
The other key information provided in the General Information
ection is “Regulatory status” and “Acceptable Daily Intake (ADI)”.
he regulatory status information is retrieved fromthegovernment
ebsites (e.g. FDA, EMEA, AAFSAPS, WHO) and other key publicly
vailable sources (e.g. Legacy documents). The speciﬁc data includ-
ng the agency name, the description, limits for use and reference
RL are extracted from the information retrieved (e.g. toxicological
roﬁles).
The Acceptable daily intake or ADI is a measure of the amount
f a speciﬁc substance (originally applied for a food additive, later
lso for a residue of a veterinary drug or pesticide) in food or
Fig. 5. Screen shot of Searchthe multiple excipients.
drinking water that can be ingested (orally) without an appre-
ciable health risk without an appreciable health risk for a life
time questionable signiﬁcance. ADI information is divided into two
components (1) general acceptable daily intake and (2) paediatric
acceptable daily intake. Thedatabase of food additives (JECFA) eval-
uated by the World Health Organization (WHO) suggests the ADI
and has made a general exception for the use of the ADI in stat-
ing that the ADI should not be considered applicable to neonates
and young infants up to 12 weeks of age (WHO, 1987). The EU
Scientiﬁc Committee for Food also recommends that intake assess-
ment of children be considered separately from that of adults
because patterns of consumption are different. ADIs should cover
the entire population including children. Considering this fact, the
STEP database provides separate sections for general and paedi-
atric speciﬁc ADIs. Any ADI information available for excipients
fromexisting literature is compiledunder “general acceptable daily
intake” and only information gathered that is speciﬁc for paediatric
population is reported in the STEP under the section for paediatric
acceptable daily intake. If no paediatric ADI information is obtained
from literature for any particular excipients then it is listed as “Not
Available”. Overall the ADI information is retrieved primarily from
for Excipients module.
S. Salunke et al. / International Journal of Pharmaceutics 457 (2013) 310–322 315
Fig. 6. Screen shot of Search Results display.
Fig. 7. Screen shot of General Information display.
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Table 1
Data ﬁelds in non-clinical section.
Data ﬁelds Examples
Study type For animals: carcinogenicity study,
immunological study, etc.; for human:
case reports, clinical trials, etc.
Species Mouse, rat, dog, human, etc.
Age Animals: juvenile, adult
Humans: children, infants, adults, etc.
Route of administration Oral, inhalation, dermal, ocular, topical,
parenteral, etc.
Dose/concentration mg, g; mg/kg; mL/kg, etc.
Duration of treatment Days, weeks, etc.
Frequency of treatment Per day, per week, etc.
Dosage regimen Single, repeated, intermittent, etc.
Kinetics data ADME data, exposure data, etc.
Adverse effects by organ system Skin, CNS, CVS, Respiratory, Renal, GIT,
etc.
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fResults and conclusion Speciﬁc experimental conditions,
recovery ﬁndings, etc. (free text)
References Bibliography
overnment sources (e.g. JECFA, WHO, EFSA) and other relevant
nformation sources. Hence it is noted “as available in the pub-
ic literature”. The information is screened to extract the speciﬁc
ttributes as name of regulatory agency, intake limit, year the limit
as assigned and reference with source URL and is organized in
abular format.
.1.2.2. Non-clinical data. This section of the database compiles
ocumented animal in vivo toxicity studies. The scope of the non-
linical compilation covers pharmacology studies, general toxicity
tudies, toxicokinetic and non-clinical pharmacokinetic studies,
eproduction toxicity studies, carcinogenicity studies and geno-
oxicity studies. Other non-clinical studies include phototoxicity,
mmunotoxicity, juvenile animal toxicity and so on. The data
ere collected from peer-reviewed publications retrieved by sys-
ematic and comprehensive literature searches in the electronic
ibliographic databases such as PubMed, Embase, Biosis Previews,
tc. and factual databases and websites such as International
rogramme on Chemical Safety (IPCS), the Canadian Centre for
ccupational Health and Safety (CCOHS) IPCS Inchem, National
oxicology Program database (NTP), ACToR (Aggregated Compu-
ational Toxicology Resource), Hazardous Substances Data Bank
HSDB), European Chemical Substances Information System (ESIS),
tc. supplemented by books of toxicological information of chem-
cals such as Sax’s Dangerous Properties of Industrial Materials,
xcipients Safety and Toxicity and others.
Table 1 depicts the data ﬁelds included in Non-Clinical data
ection of the pilot version of the STEP database.
.1.2.3. Clinical data. The clinical data compile safety and tolerabil-
ty information including epidemiological surveys of populations
xposed to a toxic chemical under normal conditions of use, in
ases of acute accidental poisoning and in occupational exposure
nd data from volunteer trials. The main sources of information
re international journal articles retrieved from systematic search-
ng of electronic databases, handbooks of toxicity information
nd poison centers. Human data on the toxicity of chemicals are
bviously more relevant to safety evaluation than those obtained
rom the exposure of experimental animals. However, controlled
xposures ofman tohazardousorpotentiallyhazardous substances
re limited by ethical considerations and information obtained by
linical or epidemiological methods must be relied on. Such data
an come from a variety of sources; case reports, case series and
oxico surveillance data often contain a high level of detail. How-
ver, they are dependent on relatively few data collection systems,
or example those of poison control centers. Exposure studies, inharmaceutics 457 (2013) 310–322
particular those involving biomonitoring, provide insight into indi-
vidual exposure to chemicals in the workplace or environment.
However, it is generally difﬁcult to link the often very low levels
of chemicals or their metabolites to health outcomes. Conversely,
health surveillance may pick up an increased burden of disease
but the degree of underlying chemical exposure is often unknown.
Volunteer studies have the advantage of well-characterized expo-
sure combinedwith informationon thepharmacokineticbehaviour
and/or effects of the compound.Hencewide ranges of sources, from
electronic journals to poison centers are explored to collect the
human toxicity and safety information.
The data ﬁelds for the clinical section are similar to those in the
non-clinical section apart from species and age category. The age
category for clinical section is mainly grouped into two groups;
adults and paediatric. As sometimes it may be more appropriate
to collect data over broad age ranges and examine the effect of
age as a continuous covariant, the paediatric age group was further
divided into different age bands (Preterm new born infants, Term
newborn infants (neonates) (0–27 days), Infants and toddlers (1
month–23 months), Pre-school children (2–5 years), School chil-
dren (6–11 years), Adolescents (12–16 or 18 years)) as per the ICH
E11 classiﬁcation (EMA, 2001). The other attributes are similar to
the non-clinical section as displayed in Table 1.
The clinical data section contains data from human studies such
as trials, human toxicology studies, poisoning cases, etc. whereas
the non-clinical section contains data from all types of toxicologi-
cal and safety assessment studies. Both the sections are structured
in table format to cover the information on experimental design,
adverse or beneﬁcial effects and ﬁnal remarks or conclusion made
from the study. As available from individual studies, key attributes
are extracted (species, sex and age, study type, dosage form, route
of administration, duration and frequency of exposure, dose or con-
centration, system organ, adverse or beneﬁcial effect and conclu-
sion). The appropriate reference or URL supports each record in the
database. Pharmacokinetic studies include information on absorp-
tion, distribution, metabolism and excretion of the substance and
any active metabolites for both the oral and intended route of
administration. The literaturemay include chapters from reference
and textbooks in addition to peer-reviewed journal articles.
3.1.2.4. In vitro data. In vitro toxicitydata canbeeffectivelyutilized
in various aspects of safety/hazard evaluation. Validated in vitro
studies can stand alone as independent indicators of risk to human
health if a comparable exposure is attained in humans and the
in vitro effects correlate with a speciﬁc adverse health effect in
humans or animals (Frazier, 1992). However there are several
issues and challenges, which limit the usefulness of in vitro data
(Crump et al., 2010). However, use of in vitro data in risk assess-
ment has great promise towards providing more efﬁcient and
cost-effective ways to test chemicals not only to ensure the highest
levels of safety, but also to reduce the reliance on animal testing
and support innovation. Moreover, it will help to alleviate the large
backlog of chemicals that have not been adequately tested.
The in vitro section in the STEP database contains the data from
invitro toxicity testing. Thedataﬁelds include thedetailed informa-
tion about the protocol used (study type, cell type), the conditions
in which the particular experiment was carried out (concentration,
controls), the results obtained and the conclusion with free text for
comments.
3.1.2.5. Regulatory References. This section of the database pro-
vides regulatory information on the excipient such as whether
the excipient is subject to any regulation concerning the use and
safety of the excipient, or whether the excipient is GRAS listed.
It provides links to national information on the regulatory status
of the substance, pertinent NRC reports, regulation pertaining to
S. Salunke et al. / International Journal of P
Table 2
Data ﬁelds in the Regulatory References section.
Data ﬁelds Description/example
Excipient name Benzoic acid
Reference Bibliography
t
a
r
a
I
p
v
i
w
t
p
t
3
f
s
s
t
t
S
t
oSource WHO, EFSA, etc.
URL Web link to the source
Year Year of the publication/document (e.g. 2012)
he excipients as published in Federal Register, worldwide food
dditive status (e.g. JECFA, WHO), assessment reports prepared by
egulatory agencies, scientiﬁc opinions and advice from regulatory
nd government agencies (e.g. EFSA, European commission, FDA).
t provides the information on accepted uses in foods and licensed
harmaceuticals where known. However the status of excipients
aries from one nation to another and appropriate regulatory bod-
es need to be consulted for guidance.With this database, end-users
ill have access to a single source of information, making it easier
o stay up to date and comply with regulations in an efﬁcient and
rompt manner. The information is extracted and organized as per
he data ﬁelds shown in Table 2.
.1.2.6. Reviews section. The reviewarticles discussing one ormore
acets of the toxicology/safety of the excipient are compiled in this
ection of the database. Most of these articles do not contain the
peciﬁc information that can be extracted as per the data ﬁelds into
he database. However, they do provide useful information about
he safety or toxicity of the excipient or group of related excipients.
ome articles may contain a complete, detailed description of the
oxicity of an excipient, othersmay address only a particular aspect
f the toxicity and others may only list the excipient in a general
Fig. 8. Screen Shots of Export Page & Reporharmaceutics 457 (2013) 310–322 317
discussion of the toxicity of a class of compounds. The list of such
references is made available with the URL link to the source.
3.1.2.7. Export data section. Generating a report of the retrieved
data was one of the essential requirements for database. Export
interface is hence provided to allow the users to create a ﬂexible,
need based information reports that can be integrated it into dif-
ferent applications. Fig. 8 represents an example of the generated
report. The data ﬁelds are provided on the export interface for the
users to be able to ﬁlter/select the ﬁelds as per their needs, gener-
ate report and save it in required format for further analysis. For
instance, to generate the report for dose and results information,
the user can select the “dose and result” check boxes and the report
will be created in required format for further statistical analysis.
4. Data collection and curation
Data gathering and curation processes are carried out in par-
allel with the development of the database application and will
continue throughout the duration of the project. In line with the
priorities set in the database development, data collection com-
menced with 10 prioritized excipients so that the content of the
pilot database is sufﬁcient to demonstrate an ability to support
searching based on queries about excipients and combination of
excipients as well as different types of adverse effects and safety
data, and combinations of these parameters. Also the large num-
ber of excipients and the limited toxicity information for many of
these have already been identiﬁed as a driver for needing to set
priorities for additional testing (Judson et al., 2009). Because the
list of excipients is so large, it was necessary to prioritize which
excipients will be included into the STEP database. In this pilot
t generated from the STEP database.
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Fig. 9. Road map for data collection.
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hase of database development, both excipients, for which sig-
iﬁcant toxicology information is limited and well-characterized
xcipients are included. The well-characterized excipients were
mportant because they allow for the development of predictive
odels for prioritization of the remaining largely uncharacterized
xcipients. The following selection criteria for excipients of interest
ere considered:
. Excipients known to be toxic/have safety issues in general
. Frequency of occurrence as contaminants or toxic in paediatrics
(where appropriate)
. Evidence in literature of toxicity in paediatrics.
The above criteria were applied to identify the excipients
or inclusion in the STEP database. The excipients were short-
isted/prioritized through polling within the Eu & US PFI members
s listed below.
List of prioritized excipients for pilot database development
1. Propylene glycol (PG)
2. Ethanol
3. Polysorbate 80
4. Benzyl alcohol
5. Parabens (propyl, methyl, ethyl and butyl)
6. Benzalkonium chloride
7. Aspartame
8. Sorbitol
9. Benzoic acid
0. Sodium benzoate
The aim was to use a selection of prioritized excipients for
eveloping data gathering methodology and for further validation
f the methodology. The peer-reviewed, published literature was
he starting point for the data collection. After extensive research
n data collection procedures, a methodology was devised to
dentify the relevant information sources (Medline, Biosis Pre-
iews, International Pharmaceutical Abstracts, Chemical Abstract,
INAHL, etc.) and to standardize resource speciﬁc search strategies
o retrieve relevant references from these sources (Brandys and
alunke, 2012; Vaconsin et al., 2012).
Fig. 9 depicts the complete roadmap for data collection. The
eﬁned search strategies were run on selected sources. There was
o time limit on the search query. All references were compiled
n the reference management software. Duplicate references were
emoved at this stage and the unique references were thoroughly
creened for relevancy as per a predeﬁned inclusion and exclusion
riteria (Salunke and Tuleu, 2010). Full texts were obtained where
eeded and read to determine if they are relevant for inclusion in
he database. The studies excluded were those that used a combi-
ation of excipients where the effect of the single excipient could
ot be deﬁned and/or those whose references were not traceable.
he data fromunpublished studieswere included only if the source
as well identiﬁed.
In order to populate the STEP database, a data extraction process
as required. Manual extraction has been proven to be both time
onsuming and labour/cost intensive and hence was decided to
utsource this to external companies. Several curation service
roviders offering manual data extraction with sufﬁcient capacity,
ood quality standards and assurance of conﬁdentiality were
valuated for use in this project. A Data Curation manual was pre-
ared to clearly deﬁne and describe the data extraction procedure,
reaking out each step in detail so that the curator understands
he content that needs curation. The manual included protocols,
olicies and procedures; the data collection instrument; and a
isting of all the data elements and their full deﬁnitions. To further
ptimize/expedite the data curation process, a standardized tem-harmaceutics 457 (2013) 310–322 319
plate containing some predeﬁned information of the experiment;
and an automatic check for formal errors was developed. This
allowed reducing the possible typing errors as well as facilitating
and speeding up the data entry. Also proper training on the
protocol and procedures, data sources, data collection instrument,
and most importantly data deﬁnitions was provided to curators.
Thesauri/ontologies were developed for excipient names, effects,
species, exposure routes, and doses to maintain the consistency
in the data entered and prevention of interpretive errors. The
key attributes for extraction include demographic information
(species, age and gender), experimental design/protocol infor-
mation (dosage form, study type, dose, route of administration,
duration of exposure, frequency of administration) and results
(adverse or beneﬁcial effects, speciﬁc remarks or conclusion of
the study). The aim was to collect a full set of information for all
prioritized excipients but thiswas not always possible. The reasons
differed from each other, but in most cases some information were
not reported in the literature. Papers in a foreign language were
translated to English where possible. If no translation of the full
paper was available, the English language abstract, was used to
extract the information. In such case, this was notiﬁed in the “Com-
ments” ﬁeld in the database. Referenceswith incomplete datawere
also included in the database to give the widest possible picture of
the studies. In such cases, information was noted as “unspeciﬁed”.
While it is consideredworthwhile to build a database compiling
safety and toxicity information already in the public domain, it was
recognized that the data in the collected preclinical toxicity reports
of pharmaceutical companies represents a potential data resource.
Efforts are underway to gather more data from legacy reports,
unpublished documents and in-house non-conﬁdential data from
pharmaceutical companies. In the long term one of the aims of the
STEP database would be to promote the sharing of data from indi-
vidual corporate entities to avoid future duplication of studies, lead
tomore efﬁcient drug development processes and at the same time
contribute to the reduction of animal studies. The pilot database
was hence populated with some data donated from industry, to
demonstrate a mechanism for sharing such data, and the potential
beneﬁts of doing so.
The quality of the data entry into the database is an essential ele-
ment andneeds a thoroughquality assurance to ensure there areno
errors in the database and that the required levels of precision and
recall are achievedor exceeded.According to this, strict quality con-
trol procedureswere implemented at the collection level, involving
proof-reading of all output documents and comprehensive check-
ing of selected curated information against the original sources.
4.1. Primary
Primary quality assurance is performed when a curator initially
enters details collected from the source information. A Curator is
an experienced scientist with Mpharm/PhD degree and knowledge
of pharmacology and toxicology. At this time the individual curator
reviewing the study, examined all data reported, to determine if the
criteria required for the study to be included in the database were
met and the information was then extracted as per the template. A
senior curator secondarily reviewed the extracted information.
4.2. Secondary
Secondary quality assurance for these data is considered to be
the review and comparison of the data extracted, and entered into
an excel spreadsheet, with the data presented in the actual refer-
ence. The secondary review process was conducted by reviewers,
but not by the person who initially entered the data. This quality
assurance effort was conducted on every record entered into the
database. In addition, reviewers assist the database team in qual-
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Table 3
The STEP database technical speciﬁcations.
Project server Connecting Server software
Web
Tom
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R
f
e
tOperating system
JDBC Red Hat Enterprise Linux
ty assurance by noting any entry data that is found to have errors
uring their day-to-day activities. The references are reallocated
or review to curators to achieve an error <0.1%.
.3. Tertiary
Tertiary quality assurance is implemented following a comple-
ion of secondary review. The methods used in this third review
nclude random visual check of data entries, several methods
f sorting by data ﬁelds to detect inconsistencies, and further
nvestigation into records that contain these inconsistencies. The
T personnel then uploaded these data into the database. Once the
eview of all the available ﬁelds is completed, through sufﬁcient
uality checks, the Excel spreadsheet is ported into Oracle.
Theoverall systemofdata curationandquality controlwasman-
ged manually currently as an interim solution and in future it is
lanned to automate at least some of the functions.
. Software development
The database application has been developed in Oracle, a
elational Database Management System (RDBMS), and the web
ront-end uses Java (Table 3). It is designed in a way to allow future
xtension.
All database connections and application logic are completely
ransparent to the Web browser. Access to the database is secured
Fig. 10. The STEP databaseapplication server Database server Application language
cat Apache Server Postgre SQLOracle Dot net
using email and the SSL protocol. This will ensure that all data
updates are secure and will enable appropriate access control for
individual users. At the registration of user access to the database
EuPFI will allow the use of database. Any kind of requests made
by the end-users via Web Browsers hit the Web Server ﬁrst. The
request is then processed by Application Interface deployed in the
server. Application Interface uses database connection and fetches
the required information and provides multiple ways of fetching
and storing the data in the database including Alerts, Query Search,
Export, user Administration, etc. The interface available is fully
web-based. The presentation layer is based onhtml/css documents.
The Javascript language extended to the popular query language is
responsible for the interface operations (Fig. 10)
6. Discussion
Over the past decade a dramatic increase has occurred in the
recognition and concern for children as a potential susceptible
population for exposure to inappropriate excipients. Developing
medicines for children ismore complex than developingmedicines
for adults and therefore it is important that a complete risk assess-
ment approach to using excipients is considered. Evidence based
risk assessmentswouldenable selectionofmoreappropriate excip-
ients. However, evidence based toxicity assessment of excipients
requires a body of evidence to be retrospectively assessed: data
about the adverse effects associated with excipients and the expo-
software operation.
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ure levels associated with those effects. As the body of knowledge
n children’s health and risk factors expands rapidly, there is
n increasing need for systematic compilation of knowledge for
urther application (screening/prioritization of the excipients to
e used in paediatric formulation, risk assessment process, etc.).
urrently there is no comprehensive resource that provides age
peciﬁc data. Review of excipient-speciﬁc and age group-speciﬁc
ata may reveal a speciﬁc age group of a particular concern from
toxicokinetic perspective. These resources are crucial for the
oxicologists and regulators involved in the risk assessment of
hemicals, which necessitates access to all the relevant literature,
nd the capability to search across toxicity databases using both
iological and chemical criteria. Different possibilities to address
hisproblemare currentlybeinganalysed. Existingpublic resources
re difﬁcult to search due to free text format; hence disaggregating
he information to make it searchable in the STEP database would
e an opportunity to add value to existing knowledge.
A pilot web-based tool is developed for storage and exchange
f safety and toxicological data for application in paediatric drug
evelopment. It is a unique database that combines clinical and
on-clinical data of excipients and allows for easy searching and
ltering of the data as per needs. It is not however, meant to serve
irectly as a data analysis/computational tool; it does not include
ny software that would allow statistical calculations. The STEP
atabase does not critically review or evaluate studies for scientiﬁc
uality. For example, the STEP database generally does not eval-
ate study design strengths, weaknesses and limitations, whether
he evidence it reports supports conclusions in a study, or whether
here is conﬂicting evidence from other studies. The STEP database
oes not derive quantitative estimates for risk assessment pur-
oses and does not integrate ﬁndings among studies. Listing of a
tudy in the STEP database does not represent an endorsement as
o the scientiﬁc quality of the study. The database is provided as a
ree Internet resource, thus ensuring easy and cost effective access
or all end-users (academic, industrial and regulatory toxicologists,
harmacologists, clinicians, researchers, regulators and others). It
s an important contribution to the rational choices of excipients
or paediatric and neonatal drug formulations. The development of
he STEP database will facilitate studies in this area and will help
dentify those excipients that take priority for evaluation in new-
orns and children and would form the basis of where the research
fforts should be directed.
Throughout the process of the database development, the end
sers were consulted and so the user requirements and testing has
een integral to the design. The schema for the database has been
eveloped in an iterative manner. The ﬁrst draft was created by
uPFI and was implemented into the web based STEP database by
VK BIO. Several improvements were made during the course of a
ilot study based on the feedback from participating EuPFI mem-
ers and domain experts.
To date, the STEP database contains a full set of data regarding
he selected 10 excipients, covering the general information link to
hysical chemical properties, and detailed toxicity and safety infor-
ation. About 700 references of clinical data, 1200 data records of
onclinical data, 500 records from in vitro experiments, 288 refer-
nces related to regulatory information and other interesting links
nd ﬁnally 233 toxicological and clinical reviews were curated in
his ﬁrst version of the database. These data can be easily retrieved
nd exported in different formats to facilitate data management
nd analyses.
The pilot data extraction study highlighted the need for a con-
ensus to be reached on how the database schema should be
opulated. The questions and answers generated during the pilot
tudy have been used to deﬁne the data entry guidelines to ensure
onsistency among the curators entering the data. The EuPFI mem-harmaceutics 457 (2013) 310–322 321
bers carried out the quality assessments and consistency checks on
the extracted data.
Key issues that the pilot database development have high-
lighted and need further efforts are extraction of quantitative data
into tabular, computable formats and mapping of data from multi-
ple sources onto standard terms and using predeﬁned vocabularies
or ontologies. The design should involve compromises between
completeness and comprehensiveness and curated versus unﬁl-
tered content and has a query language that exploits this type of
information. The largest challenge is the desire of the users to have
more detailed information on many excipients. With these issues
have come concerns about how to provide the long-term mainte-
nanceandoperationsof this infrastructure. Toenable the long-term
sustainability of the STEP database, it is imperative to develop a
strategic approach that involves users. There is a genuine need to
involve the users, since they are served by this infrastructure and
any decisions about alternative funding models might affect their
work and research. The STEP database needs periodic solicitation of
feedback to ensure the infrastructure and services continue to serve
the needs of the scientiﬁc community. The success of the database
will depend heavily on continuous input from the industry, aca-
demics, hospitals, regulatory agencies and related communities
about their needs and priorities. Hence, the feedback on the utility
of the database and how it can be improved in subsequent releases
is encouraged. More effort and coordination is needed in order
to fully address the issue of the STEP database sustainability and
ensure this valuable resource is available in the future to continue
supporting the excipients research and fostering innovation.
In conclusion, to the best of our knowledge, the presented
database is the only publicly available readily accessible source
presenting the safety and toxicity information of excipients with
paediatric element included. It is anticipated that this source will
prove to be a useful platform for data retrieval and management
and data exchange of excipient safety information. It will serve as
an excellent source of diligently curated data for development of
safer medicines for children. For instance, it has already shown to
be of value during the development of “1st excipient monograph of
propylene glycol” by ESNEE (Vaconsin et al., 2013). The intention
is for the STEP database to be useful to those people responsible
for developing medicines designed for children, as well as for those
responsible for manipulating adult licensed medicines for off-label
use in children. However, in addition to the paediatric data, the
database includes adult, animal, and in vitro data and so also can be
for other purposes (e.g. selection of species for toxicity studies, tox-
icity prediction studies, etc.). Therefore, theusers are encouraged to
consider this as ageneral database that couldbeapplicable for other
areas of toxicology. Such a database would serve as a valuable tool
for archiving and also facilitate exchange of data from any safety
and toxicological studies suchasESNEEproject (Turner andStorme,
2012). The STEP database needs periodic solicitation of feedback to
ensure the infrastructure and services continue to serve the needs
of the scientiﬁc community. Thesuccessof thedatabasewill depend
heavily on continuous input from the industry, academics, hospi-
tals, regulatoryagenciesandrelatedcommunities about theirneeds
and priorities. The feedback on the utility of the database and how
it can be improved in subsequent releases is encouraged.
Following the pilot described in this paper a follow-on long term
project has started. The focus of the ongoing project is to increase
the number of excipients in the existing database so that a database
large enough to be of practical research use will be available. Fol-
lowing to that, databasemaintenance, updating and expansionwill
continue. The database is available to a large circle of the users
(toxicologists, clinicians, regulators, researchers, etc.) and feedback
will be collected on a regular basis to capture the needed addi-
tional changes or requirements. Furthermore, currently the only
source of information is published literature, however it is well
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cknowledged that the vast amount of information is held within
he drug companies. Hence companies are encouraged to step for-
ard towards a collaborative effort to contribute their in-house
on-conﬁdential data into the STEP database to avoid the duplica-
ion of the efforts and save money and time involved in toxicity
esting.
This paper is the second in a series of articles presenting
he development of the pilot STEP database. Subsequent articles
ill present the challenges associated with the development and
ethodology developed to overcome those, along with the beta
esting feedback from the end-users.
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